Dianne Nast, founder of NastLaw, was named as co-lead counsel in the Generic Digoxin and Doxycycline Antitrust Litigation. Roberta Liebenberg of Fine, Kaplan, and Black was appointed as co-lead counsel alongside Ms. Nast.

The appointment is being hailed as a major advancement in diversity, as this is one of the only known instances of two women being appointed to lead a federal multidistrict antitrust litigation. The appointment was made by U.S. District Judge Cynthia Rufe of the Eastern District of Pennsylvania.

The court expects that the leadership will provide opportunities for attorneys not named to the plaintiff’s steering committee, particularly less-senior attorneys, to participate meaningfully and efficiently in the MDL, including through participation in any committees within the plaintiff’s steering committee and in determining which counsel will argue any motions before the court,” Judge Rufe said.

Five women were also appointed to the 12-member steering committee.

About the Generic Digoxin and Doxycycline Antitrust Litigation

The lawsuit alleges that several drug companies, including Allergan and Mylan, illegally colluded to raise the price of the medications digoxin and doxycycline. Doxycycline prices increased an incredible 8,281 percent between October 2013 and April 2o14, and the price of digoxin pills increased ten fold during a similar time period.

Both medications are included on the World Health Organization’s list of essential medicines. The lawsuit is seeking an injunction to stop the price fixing conspiracy under federal antitrust law, and would benefit any individuals or companies who bought or paid for the two drugs since October 2012.

Read the full article by the Legal Intelligencer.

For more information on NastLaw’s history of success in similar antitrust cases, visit our antitrust information page.